Indegene (INDGN) Aperçu de l'action
Indegene Limited est une société de commercialisation des sciences de la vie en Inde, aux États-Unis, en Europe et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 4/6 |
| Performances passées | 2/6 |
| Santé financière | 6/6 |
| Dividendes | 3/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour INDGN à partir de nos contrôles de risques.
INDGN Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
₹808.94
FV
37.1% sous-évalué décote intrinsèque15.98%
Revenue growth p.a.
200
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Indegene Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹508.55 |
| Plus haut sur 52 semaines | ₹632.90 |
| Plus bas sur 52 semaines | ₹414.00 |
| Bêta | 0.76 |
| Variation sur 1 mois | 1.98% |
| Variation sur 3 mois | 4.84% |
| Variation sur 1 an | -15.26% |
| Variation sur 3 ans | n/a |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | 12.51% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 14
INDGN: Upcoming Tax Assessment Outcome Will Support Future Upside
Analysts have raised Indegene's price target from ₹568.57 to ₹592.43, reflecting updated assumptions that include slightly lower discount and revenue growth rates, a marginally higher profit margin, and a modestly lower future P/E multiple. What's in the News The Income Tax Department has issued a final assessment order for Assessment Year 2023-24 with an income tax demand of ₹436.88441 million, following transfer pricing adjustments of ₹1,234.110559 million.Article d’analyse • May 10
Investors Can Find Comfort In Indegene's (NSE:INDGN) Earnings Quality
The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...Mise à jour du récit • Apr 25
INDGN: Upcoming Results Review And Dividend Decision Will Support Future Upside
Indegene's analyst price target has edged down by about ₹3 per share as analysts fine-tune assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples in their updated models. What's in the News A board meeting is scheduled for April 29, 2026, to review and approve the audited consolidated financial results for Indegene and its subsidiaries for the quarter and year ended March 31, 2026, prepared under INDAS, along with the auditor's report (company filing).Mise à jour du récit • Apr 08
INDGN: Upcoming Board Review And RSU Allotment Will Support Future Upside
Analysts now set their price target for Indegene at ₹571.57 versus ₹603.00 earlier. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.
Nouveau récit • Apr 04
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?Recent updates
Mise à jour du récit • May 14
INDGN: Upcoming Tax Assessment Outcome Will Support Future Upside
Analysts have raised Indegene's price target from ₹568.57 to ₹592.43, reflecting updated assumptions that include slightly lower discount and revenue growth rates, a marginally higher profit margin, and a modestly lower future P/E multiple. What's in the News The Income Tax Department has issued a final assessment order for Assessment Year 2023-24 with an income tax demand of ₹436.88441 million, following transfer pricing adjustments of ₹1,234.110559 million.Article d’analyse • May 10
Investors Can Find Comfort In Indegene's (NSE:INDGN) Earnings Quality
The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...Mise à jour du récit • Apr 25
INDGN: Upcoming Results Review And Dividend Decision Will Support Future Upside
Indegene's analyst price target has edged down by about ₹3 per share as analysts fine-tune assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples in their updated models. What's in the News A board meeting is scheduled for April 29, 2026, to review and approve the audited consolidated financial results for Indegene and its subsidiaries for the quarter and year ended March 31, 2026, prepared under INDAS, along with the auditor's report (company filing).Mise à jour du récit • Apr 08
INDGN: Upcoming Board Review And RSU Allotment Will Support Future Upside
Analysts now set their price target for Indegene at ₹571.57 versus ₹603.00 earlier. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.Nouveau récit • Apr 04
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Mar 24
INDGN: Steady Fair Value And Upcoming Board Review Will Support Upside Potential
Analysts have kept Indegene's fair value estimate steady at ₹603.0, with only marginal tweaks to assumptions such as the discount rate and future P/E. This reflects fine tuning of their valuation framework rather than a major shift in view.
Nouveau récit • Mar 14
Indegene deep undervalued stock
At ₹429–430 levels (near 52-week low), Indegene offers excellent risk-reward for 12–24 month horizon. Explosive long-term growth (35% sales CAGR, 68% profit CAGR), first $100M quarter, near-zero debt, and powerful AI/GenAI positioning in the high-growth life-sciences sector make this a high-quality compounder.Mise à jour du récit • Mar 05
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have trimmed their price target for Indegene slightly from about ₹606 to ₹603, reflecting modest tweaks to fair value, discount rate and future P/E assumptions while keeping revenue growth and profit margin expectations effectively unchanged. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for the quarter ended December 31, 2025 under IND AS, along with the auditors' limited review report (Key Developments).Mise à jour du récit • Feb 19
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Analysts have kept their fair value estimate for Indegene steady at ₹605.86 per share, with only minor tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding this price target reaffirmation. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for Indegene and its subsidiaries for the quarter ended December 31, 2025, prepared under IND AS, along with the auditors' limited review report (company filing).Mise à jour du récit • Feb 04
INDGN: Upcoming Board And Shareholder Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene from ₹609.63 to ₹605.86, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News A board meeting is scheduled for January 29, 2026, to review unaudited consolidated financial results for the quarter ended December 31, 2025, under INDAS, along with the auditors' limited review report (company filing).Article d’analyse • Feb 02
Earnings Miss: Indegene Limited Missed EPS By 8.1% And Analysts Are Revising Their Forecasts
Last week saw the newest third-quarter earnings release from Indegene Limited ( NSE:INDGN ), an important milestone in...Mise à jour du récit • Jan 08
INDGN: Expanded Consulting Practice And Upcoming Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene slightly from ₹610.25 to ₹609.63. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E that keep the overall valuation view broadly intact.Mise à jour du récit • Dec 23
INDGN: Upcoming Board And Shareholder Actions Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have slightly reduced their price target on Indegene by approximately ₹2 to about ₹610, reflecting marginal adjustments to discount rate and profit margin assumptions, along with a modest increase in long term revenue growth expectations. What's in the News Indegene has expanded its Consulting Practice to provide integrated strategy and transformation support for life sciences clients, aiming to deliver both strategic insight and hands on implementation across the value chain (Key Developments).Mise à jour du récit • Dec 09
INDGN: Upcoming Board Meeting Will Drive Continued Positive Momentum
Analysts have modestly raised their price target on Indegene by about 1 percent to approximately $612, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite largely stable profit margin and discount rate assumptions. What's in the News Board meeting scheduled on October 30, 2025 to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025 and consider equity allotments under ESOP 2020 and RSU 2020 schemes (company filing) Expansion of Indegene's Consulting Practice to provide integrated strategy and transformation support for life sciences clients facing large scale, technology driven change across the value chain (company announcement) Strategic partnership with Datavant to integrate its health data network into Indegene's NEXT Patient Recruitment platform, aiming to speed up clinical trial enrollment and improve patient recruitment, particularly in rare diseases (Datavant and company announcement) Valuation Changes The fair value estimate has risen slightly to about ₹612 per share from roughly ₹608 per share, reflecting a modest upward revision.Mise à jour du récit • Nov 25
INDGN: Upcoming Board Meeting and Expansions Will Drive Continued Momentum
Analysts have slightly adjusted their price target for Indegene, lowering it from ₹609.57 to ₹608.14 as a result of modest revisions in growth and profitability assumptions. What's in the News A board meeting is scheduled for October 30, 2025 to consider consolidated and standalone financial results as well as ESOP/RSU allotments (Board Meeting).Mise à jour du récit • Nov 10
INDGN: Rising Revenue and Business Expansion Will Drive Continued Outperformance
Narrative Update on Indegene Price Target Analysts have lowered their price target for Indegene from ₹644.67 to ₹609.57, citing revised expectations on future profitability and growth dynamics. What's in the News Board meeting scheduled for October 30, 2025, to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025.Article d’analyse • Nov 02
Indegene Limited Beat Revenue Forecasts By 5.6%: Here's What Analysts Are Forecasting Next
The quarterly results for Indegene Limited ( NSE:INDGN ) were released last week, making it a good time to revisit its...Article d’analyse • Jul 23
Getting In Cheap On Indegene Limited (NSE:INDGN) Is Unlikely
There wouldn't be many who think Indegene Limited's ( NSE:INDGN ) price-to-earnings (or "P/E") ratio of 32.5x is worth...Nouveau récit • May 11
M&A And Cortex Integration Will Expand Enterprise Opportunities
M&A activities and AI integration signal innovation and efficiency, likely boosting topline growth and improving net margins through cost reductions.Article d’analyse • May 03
Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year
Indegene Limited ( NSE:INDGN ) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to...Article d’analyse • Feb 25
Indegene Limited's (NSE:INDGN) Price Is Out Of Tune With Earnings
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 26x, you may consider...Rendement pour les actionnaires
| INDGN | IN Life Sciences | IN Marché | |
|---|---|---|---|
| 7D | -1.5% | 1.6% | 0.5% |
| 1Y | -15.3% | 3.5% | -0.5% |
Rendement vs Industrie: INDGN a sous-performé le secteur Indian Life Sciences qui a rapporté 3.5 % au cours de l'année écoulée.
Rendement vs marché: INDGN a sous-performé le marché Indian qui a rapporté -0.5 % au cours de l'année écoulée.
Volatilité des prix
| INDGN volatility | |
|---|---|
| INDGN Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
Cours de l'action stable: INDGN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de INDGN ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1998 | 4,158 | Manish Gupta | www.indegene.com |
Indegene Limited est une société de commercialisation des sciences de la vie qui opère en Inde, aux États-Unis, en Europe et dans le monde entier. Elle opère à travers trois segments : Enterprise Medical Solutions, Enterprise Commercial Solutions et Omnichannel Activation & Others. L'entreprise développe des produits biotechnologiques et des dispositifs médicaux pour des sociétés biopharmaceutiques, des sociétés biotechnologiques émergentes et des sociétés de dispositifs médicaux.
Indegene Limited Résumé des fondamentaux
| INDGN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹122.06b |
| Bénéfices(TTM) | ₹4.01b |
| Recettes(TTM) | ₹35.11b |
30.4x
Ratio P/E3.5x
Ratio P/SLe site INDGN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| INDGN compte de résultat (TTM) | |
|---|---|
| Recettes | ₹35.11b |
| Coût des recettes | ₹0 |
| Marge brute | ₹35.11b |
| Autres dépenses | ₹31.09b |
| Les revenus | ₹4.01b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 16.71 |
| Marge brute | 100.00% |
| Marge bénéficiaire nette | 11.43% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de INDGN?
Voir les performances historiques et les comparaisonsDividendes
0.4%
Rendement actuel des dividendes13%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 03:54 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Indegene Limited est couverte par 14 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Deep Shah | 360 ONE Capital Market Private Limited |
| Rajiv Berlia | Citigroup Inc |